Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03076346 · ClinicalTrials.gov registry record
Neural Biomarkers of Clozapine Response
A clinical trial, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 41
- Enrollment target
NCT03076346: Completed study, sponsored by University of Pittsburgh.
NCT03076346 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 41 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03076346 has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 41 participants
- Enrollment target
Study Summary
Clozapine has consistently shown to be a superior drug for psychosis in patients who do not respond to other treatments, but its mechanism of action remains unknown. The overall goal of this study is to examine the functional neural circuitry that underlies successful treatment with clozapine, which may lead to the identification of biomarkers that will allow for more efficient use of clozapine, as well as additional treatment targets for patients with refractory illness.
Primary Outcome
The investigators will examine the functional circuitry associated with a reduction of psychotic symptoms assessed with the Brief Psychiatric Rating Scale.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2017-09-01 |
| Est. Completion | 2020-12-31 |
What the finished NCT03076346 record still lists
NCT03076346 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 41 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03076346 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03076346 about?
NCT03076346 is a clinical study titled "Neural Biomarkers of Clozapine Response". Clozapine has consistently shown to be a superior drug for psychosis in patients who do not respond to other treatments, but its mechanism of action remains unknown. The overall goal of this study is to examine the functional neural circuitry that underlies successful treatment with clozapine, which...
What is the current status of trial NCT03076346?
This trial is currently completed. The enrollment target is 41 participants. The study started on 2017-09-01. Estimated completion is 2020-12-31.
Who is sponsoring clinical trial NCT03076346?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI